KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Financing Activities (2018 - 2026)

Moderna (MRNA) has disclosed Cash from Financing Activities for 9 consecutive years, with $17.0 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 325.0% year-over-year to $17.0 million; the TTM value through Mar 2026 reached $606.0 million, up 1217.39%, while the annual FY2025 figure was $593.0 million, 958.93% up from the prior year.
  • Cash from Financing Activities hit $17.0 million in Q1 2026 for Moderna, down from $581.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $581.0 million in Q4 2025 and bottomed at -$1.3 billion in Q2 2022.
  • Average Cash from Financing Activities over 5 years is -$244.6 million, with a median of -$3.0 million recorded in 2024.
  • Year-over-year, Cash from Financing Activities tumbled 51950.0% in 2022 and then surged 19466.67% in 2025.
  • Moderna's Cash from Financing Activities stood at -$438.0 million in 2022, then soared by 75.11% to -$109.0 million in 2023, then skyrocketed by 97.25% to -$3.0 million in 2024, then soared by 19466.67% to $581.0 million in 2025, then crashed by 97.07% to $17.0 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $17.0 million, $581.0 million, and -$1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.